Advertisement

Bulletin of Experimental Biology and Medicine

, Volume 161, Issue 5, pp 706–710 | Cite as

Nanohybride Materials Based on Magnetite-Gold Nanoparticles for Diagnostics of Prostate Cancer: Synthesis and In Vitro Testing

  • A. E. MachulkinEmail author
  • A. S. Garanina
  • O. A. Zhironkina
  • E. K. Beloglazkina
  • N. V. Zyk
  • A. G. Savchenko
  • V. E. Kotelyanskii
  • A. G. Mazhuga
BIOTECHNOLOGIES

We synthesized a fluorescence conjugate and modified magnetite-gold nanoparticles carrying prostate specific membrane antigen (PSMA) as the ligand. Analysis of their binding to human prostate cancer cell lines PC-3 (PSMA) and LNCaP (PSMA+) showed selective interaction of the synthesized conjugate and modified nanoparticles with LNCaP cells. These findings suggest that these nanoparticles can be used in tissue-specific magnetic-resonance imaging.

Key Words

nanoparticles prostate-specific membrane antigen diagnostics magnetic-resonance imaging (MRI) prostate cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Colombatti M, Grasso S, Porzia A, Fracasso G, Scupoli MT, Cingarlini S, Poffe O, Naim HY, Heine M, Tridente G, Mainiero F, Ramarli D. The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways. PLoS One. 2009;4(2):e4608.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Etame AB, Diaz RJ, O’Reilly MA, Smith CA, Mainprize TG, Hynynen K, Rutka JT. Enhanced delivery of gold nanoparticles with therapeutic potential into the brain using MRI-guided focused ultrasound. Nanomedicine 2012;8(7):1133-1142.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 2004;22(8):969-976.CrossRefPubMedGoogle Scholar
  4. 4.
    Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, Severens JL, Barentsz JO. The diagnostic ac-curacy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin. Radiol. 2008;63(4):387-395.CrossRefPubMedGoogle Scholar
  5. 5.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J. Clin. 201;61(2):69-90.Google Scholar
  6. 6.
    Kireev I, Lakonishok M, Liu W, Joshi VN, Powell R, Belmont AS. In vivo immunogold labeling confirms large-scale chromatin folding motifs. Nat. Methods 2008;5(4):311-313.PubMedGoogle Scholar
  7. 7.
    Kularatne SA, Wang K, Santhapuram HK, Low PS. Prostatespecific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol. Pharm. 2009;6(3):780-789.CrossRefPubMedGoogle Scholar
  8. 8.
    Linn MM, Ball RA, Maradiegue A. Prostate-specific antigen screening: friend or foe? Urol. Nurs. 2007;27(6):481-489.PubMedGoogle Scholar
  9. 9.
    Nakajima T, Mitsunaga M, Bander NH, Heston WD, Choyke PL, Kobayashi H. Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibodyindocyanine green (ICG) conjugate. Bioconjug. Chem. 2011;22(8):1700-1705.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Shibutani ST, Yoshimori T. A current perspective of autophagosome biogenesis. Cell Res. 2014;24(1):58-68.CrossRefPubMedGoogle Scholar
  11. 11.
    Tse BW, Cowin GJ, Soekmadji C, Jovanovic L, Vasireddy RS, Ling MT, Khatri A, Liu T, Thierry B, Russell PJ. PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer. Nanomedicine (Lond). 2015;10(3):375-386.CrossRefGoogle Scholar
  12. 12.
    Yigit MV, Moore A, Medarova Z. Magnetic nanoparticles for cancer diagnosis and therapy. Pharm. Res. 2012;29(5):1180-1188.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Yu H, Chen M, Rice PM, Wang SX, White RL, Sun S. Dumbbell-like bifunctional Au-Fe3O4 nanoparticles. Nano Lett. 2005;5(2):379-382.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhang H. Quantum dot-A10 RNA aptamer-doxorubicin conjugate. MICAD. 2008, Aug 25.Google Scholar
  15. 15.
    Zhu Y, Sun Y, Chen Y, Liu W, Jiang J, Guan W, Zhang Z, Duan Y. In vivo molecular MRI imaging of prostate cancer by targeting PSMA with polypeptide-labeled superparamagnetic iron oxide nanoparticles. Int. J. Mol. Sci. 2015;16(5):9573-9587.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • A. E. Machulkin
    • 1
    • 2
    Email author
  • A. S. Garanina
    • 2
  • O. A. Zhironkina
    • 3
  • E. K. Beloglazkina
    • 1
    • 2
  • N. V. Zyk
    • 1
  • A. G. Savchenko
    • 2
  • V. E. Kotelyanskii
    • 1
  • A. G. Mazhuga
    • 1
    • 2
  1. 1.Laboratory of Tissue-Specific Ligands, Faculty of ChemistryM. V. Lomonosov Moscow State UniversityMoscowRussia
  2. 2.Laboratory of Biomedical Nanomaterials, National University of Science and Technology, Moscow Institute of Steel and Alloys (NUST MISiS)MoscowRussia
  3. 3.Department of Electronic MicroscopyA. N. Belozersky Research Institute of Physical and Chemical BiologyMoscowRussia

Personalised recommendations